Docetaxel and Sirolimus in Patients With Advanced Malignancies
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study to find the highest tolerated dose of the
combination of Taxotere (docetaxel) and Rapamycin (sirolimus) when given to patients with
advanced cancer.
Researchers also want to find highest tolerated dose of the combination of docetaxel,
sirolimus, and prednisone when given to patients with advanced prostate cancer. The safety of
both drug combinations will also be studied.